APHA Buy And Sells

House Positions for C:APHA from 20181116 to 20181116

House	Bought	$Val	Ave	Sold	$Val	Ave	Net	$Net
15 UBS	4,100	53,616	13.077	631,470	8,090,056	12.811	-627,370	8,036,440
1 Anonymous	1,046,336	13,536,223	12.937	1,207,637	15,646,193	12.956	-161,301	2,109,970
39 Merrill Lynch	497,666	6,424,346	12.909	647,764	8,375,397	12.93	-150,098	1,951,051
53 Morgan Stanley	44,414	570,453	12.844	108,691	1,387,496	12.766	-64,277	817,043
2 RBC	558,325	7,237,164	12.962	578,739	7,493,684	12.948	-20,414	256,520
13 Instinet	74,710	968,617	12.965	91,200	1,186,607	13.011	-16,490	217,990
101 SG Capital	400	5,188	12.97	13,700	176,860	12.909	-13,300	171,672
65 Goldman	1,300	16,412	12.625	10,796	137,306	12.718	-9,496	120,894
14 ITG	10,100	132,885	13.157	18,999	243,600	12.822	-8,899	110,715
57 Interactive	4,820	62,561	12.979	9,476	121,564	12.829	-4,656	59,003
143 Pershing	9,305	120,424	12.942	11,209	145,508	12.981	-1,904	25,084
76 Industrial Alliance	0			1,000	13,167	13.167	-1,000	13,167
72 Credit Suisse	16,500	214,451	12.997	17,400	225,953	12.986	-900	11,502
56 Edward Jones	375	4,846	12.923	815	10,443	12.813	-440	5,597
70 Manulife	250	3,208	12.832	250	3,185	12.74	0	-23
62 Haywood	2,000	25,600	12.80	1,000	13,380	13.38	1,000	-12,220
48 Laurentian	1,000	12,930	12.93	0			1,000	-12,930
22 Fidelity	1,000	12,757	12.757	0			1,000	-12,757
35 Friedberg	1,500	20,055	13.37	0			1,500	-20,055
36 Latimer	4,918	63,137	12.838	3,157	41,224	13.058	1,761	-21,913
28 BBS	8,888	114,989	12.938	5,591	72,113	12.898	3,297	-42,876
89 Raymond James	7,750	99,433	12.83	250	3,200	12.80	7,500	-96,233
33 Canaccord	12,520	160,912	12.852	3,100	39,650	12.79	9,420	-121,262
88 Credential	50,012	650,537	13.008	25,746	336,160	13.057	24,266	-314,377
19 Desjardins	59,505	770,131	12.942	30,963	400,312	12.929	28,542	-369,819
99 Jitney	191,600	2,477,503	12.931	157,700	2,048,521	12.99	33,900	-428,982
80 National Bank	170,917	2,208,146	12.919	104,845	1,350,711	12.883	66,072	-857,435
9 BMO Nesbitt	254,885	3,309,134	12.983	176,514	2,294,060	12.996	78,371	-1,015,074
4 Cantor Fitz	100,000	1,274,040	12.74	0			100,000	-1,274,040
79 CIBC	1,771,751	22,901,910	12.926	1,639,724	21,235,570	12.951	132,027	-1,666,340
124 Questrade	301,658	3,917,467	12.986	162,392	2,100,301	12.934	139,266	-1,817,166
85 Scotia	421,209	5,459,180	12.961	233,688	3,028,810	12.961	187,521	-2,430,370
7 TD Sec	952,858	12,308,431	12.917	688,756	8,915,655	12.945	264,102	-3,392,776
TOTAL	6,582,572	85,136,686	12.934	6,582,572	85,136,686	12.934	0	0

APHRIA INC. (APHA): INSIDERS SMELL A BARGAIN?

November 14 2018

Aphria Inc. (APHA) hit an intraday high Tuesday at $11.46. The shares finished at $10.3, after trading as low as $10.24 earlier in the session. It dropped -8.69% in recent trade and currently has a stock-market value of $2.39B. Trading activity significantly improved as the volume at ready counter increased to 3,191,223 shares versus 2,790,285 in average daily trading volume over the past 20 days. So far this year, the volume has averaged about 1,402,368 shares. The stock is now 65.33% above against its bear-market low of $6.23 on November 16, 2017. It has retreated -92.91% since it’s 52-week high of $19.87 reached in January. Now the market price is up 43.25% on the year and down -30.17% YTD.

APHA’s 50 day simple moving average (SMA 50) price is $13.64 and its 200-day simple moving average (SMA 200) price is $10.54. The company’s stock currently has a total float of 214.71M shares. Its weekly volatility is hovering around 9.1% and felt 13.51% volatility in price over a month. On the upside, the share price will test short term resistance at around $11.09. On a downside, the stock is likely to find some support, which begins at $9.87. The failure to get near-term support could push it to $9.45.

Wall Street’s most bullish Aphria Inc. (NYSE:APHA) analysts are predicting the share price to blow past $33 per share during the next 12 months. The current median share price forecast by them is $25.75, suggesting that the stock could increase 150% in that time frame. The average price target of $25.69 calls for a nearly 149.42% increase in the stock price.

When looking at valuations, Aphria Inc. (APHA) has a pricey P/E of 76.3x as compared to industry average of 28x. Also, it is trading at rather expensive levels at just over 2.47x price/book and 86.25x price/sales.

APHA last reported earnings on October 12, 2018 when it released Aug-18 results that exceeded expectations. The company raked in $0.06 per share, -100.03% change on the same period last year. That was better than consensus for -$0.06. Revenue for the recent quarter stood at $13.29 million, up 117% on last year and below the $14 million predicted by analysts. For this quarter, Wall Street analysts forecast revenue in a range of $10.4 million to $12 million, which should be compared with $0 generated last year.

Money Managers Are Loading Up On Aphria Inc. (APHA)

Aphria Inc. (NYSE:APHA) enjoyed a 53.07% run-up in share price since hitting record low of $6.23. The stock managed -7.38% fall and now stands at $9.54 as of 11/14/2018. At recent session, the prices were hovering between $9.26 and $10.24. This company shares are -100% up from its target price of $0 and the current market capitalization stands at $2.22B. The recent change has given its price a -30.08% deficit over SMA 50 and -51.99% deficit over its 52-week high. The stock witnessed -33.89% declines, 21.07% gains and 2.84% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found APHA’s volatility during a week at 9.22% and during a month it has been found around 13.35%.

Aphria Inc. (APHA) Top Holders

Institutional investors currently hold around $4 million or 0% in APHA stock. Look at its top three institutional owners. Hellman Jordan Management Co Inc /Ma/ owns $3.25 million in Aphria Inc., which represents roughly 0.15% of the company’s market cap and approximately 81.13% of the institutional ownership. Similar statistics are true for the second largest owner, Mcgowan Group Asset Management, Inc., which owns 24,888 shares of the stock are valued at $256 thousand. The third largest holder is Highpoint Advisor Group Llc, which currently holds $130 thousand worth of this stock and that ownership represents nearly 0.01% of its market capitalization.

Aphria Inc. 13F Filings

At the end of June reporting period, 6 institutional holders increased their position in Aphria Inc. (NYSE:APHA) by some 31,746 shares, 3 decreased positions by 548 and 4 held positions by 327,135. That puts total institutional holdings at 359,429 shares, according to SEC filings. The stock grabbed 4 new institutional investments totaling 16,496 shares while 1 institutional investors sold out their entire positions totaling 300 shares.

Aphria Inc. (APHA) Analyst Guide

Several analysts have released their opinion on Aphria Inc. (NYSE:APHA), with 4 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 3 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.43 average brokerage recommendation.

Lawsuit throws German cannabis program into limbo; deadline delayed to Dec. 11

Advantage for importers

Another delay in handing out domestic cultivation licenses would give an advantage to international companies currently supplying the German medical cannabis market, as locally produced MMJ could be pushed to 2020 or beyond.

Companies from Canada and the Netherlands are exporting a record amount of medical cannabis to Germany.

Another large Canadian medical cannabis company, Ontario-based Aphria, announced last week its intention to buy Densborn, Germany-based CC Pharma for 24.5 million euros ($28 million) in cash on closing and another 23.5 million euros if certain performance milestones are met.

Aphria aims to obtain its European Union Good Manufacturing Practices (GMP) – an essential European quality standard – joining Aurora, Maricann, Cronos, Tilray and Canopy Growth.

Only EU GMP-certified companies can export medical cannabis products to Germany.

Advantage 

Lawsuit throws German cannabis program into limbo; deadline delayed to Dec. 11

Another lawsuit challenging the application process to grow medical cannabis in Germany could throw the already-delayed domestic cultivation plans even further into a state of uncertainty.

In an update to the public tender, the German Federal Institute for Drugs and Medical Devices (BfArM) disclosed a lawsuit filed in the Dusseldorf Higher Regional Court (OLG Dusseldorf).

The current deadline to apply – already pushed from Oct. 22 to Nov.  5 – stands at Dec. 11.

According to the BfArM notice, the case is expected to be decided around April 2019.

On Thursday, BfArM moved the date until which companies must bind their offers grow medical marijuana to April, so it is unclear when the winners of the application process will be awarded.

Germany had intended to award the country’s first domestic licenses in the first quarter of next year.

A court ruling in favor of the plaintiff could result in the entire program starting from scratch.

“It does, to a great extent, put the current tender in limbo. The tender has already been delayed multiple times, including last week,” said Deepak Anand, vice president of Toronto consultancy Cannabis Compliance.

The first application process started in 2017 and was delayed until March 2018, after a plaintiff successfully sued the government over the process.

Up for grabs are 13 contracts, or ” lots,” and a single company can get up to five contracts. Each lot calls for 200 kilograms (440 pounds) to start.

Advantage for importers

Another delay in handing out domestic cultivation licenses would give an advantage to international companies currently supplying the German medical cannabis market, as locally produced MMJ could be pushed to 2020 or beyond.

Companies from Canada and the Netherlands are exporting a record amount of medical cannabis to Germany.

Canadian multinationals that include Tilray, Cronos Group, Aurora Cannabis and Canopy Growth are establishing cultivation centers in places such as Denmark, Portugal and Israel – and much of that production could end up supplying the German market.

Another large Canadian medical cannabis company, Ontario-based Aphria, announced last week its intention to buy Densborn, Germany-based CC Pharma for 24.5 million euros ($28 million) in cash on closing and another 23.5 million euros if certain performance milestones are met.

Aphria aims to obtain its European Union Good Manufacturing Practices (GMP) – an essential European quality standard – joining Aurora, Maricann, Cronos, Tilray and Canopy Growth.

Only EU GMP-certified companies can export medical cannabis products to Germany.

Source